Licensing & Business-Development Counterparties
Capital & market ecosystem — Finance & capital
The corporate-development, licensing, and partnering functions that in- and out-license products and form manufacturing and development partnerships. Every such deal carries quality obligations that outlast the signature — the quality agreement, the tech transfer, and the accountability that does not move with the licence. SPEQ explains those obligations, not the deal terms.
What this page does not claim
The rings are SPEQ’s map of who operates in the regulated ecosystem, not a legal or regulatory classification. Where an organization type already has a canonical page, this points at it rather than describing it twice.
Licensing and partnership deals carry quality obligations — the quality agreement, the tech transfer, and non-transferable accountability — that determine whether the partnered product can actually be made and supplied compliantly.
The regulated-relevance test — an adjacent subject belongs only when it materially affects one of ten regulated concerns.
- Negotiate in- and out-licensing of products and technologies
- Structure manufacturing, development, and co-promotion partnerships
- Own the quality-agreement and tech-transfer provisions of a deal
- Manage the ongoing partner relationship and its quality obligations
A licensing or partnership deal creates a lasting quality relationship: the quality agreement defines who does what, who tells whom about a deviation or change, and who is accountable — the ICH Q10 and outsourced-activity expectations made contractual.
A technology transfer is where a deal’s quality risk concentrates: the receiving unit must reproduce a validated process, and a poorly scoped transfer surfaces as deviations long after the deal closes.
Accountability for the product’s quality stays with the authorisation holder, so a licence-in brings the partner’s quality history and obligations with it — which means diligence on the quality agreement and the transferring process is diligence on the deal itself, not a formality to be closed after signing.
- A weak or absent quality agreement that leaves deviation, change, and audit rights unclear
- Under-scoped technology transfer that surfaces as chronic deviations post-deal
- Assuming a licence-in transfers the product without its quality obligations and history
The 2 standards SPEQ maps to this org type’s quality interface, across 1 regulatory body: ICH.
FREQUENTLY ASKED
What quality obligations does a licensing deal create?
A lasting quality relationship governed by the quality agreement — who performs which activities, who notifies whom of deviations and changes, audit and access rights, and who is accountable. These make the ICH Q10 pharmaceutical-quality-system and outsourced-activity expectations contractual, and they outlast the deal signature.
Does licensing-in a product transfer its quality history?
Effectively, yes. Accountability for a product’s quality stays with the authorisation holder, so a licence-in brings the partner’s quality obligations — and often its history and open commitments — with it. That is why diligence on the quality agreement and the transferring process is diligence on the deal itself, not a formality.